GlaxoSmithKline (GSK) aims to cut $2.5 billion in costs through supply chain and procurement reforms, including a 5-year logistics contract with Kuehne + Nagel featuring four regional Logistics Control Centers. Former CEO Andrew Witty emphasized sustained cost pressure, while current CEO Luke Miels champions a 'product-centric' model targeting more than £40 billion in revenue by 2031. The initiative follows industry trends seen at Novartis and Teva, where supply chain improvements were expected to yield hundreds of millions in savings.
According to www.fiercepharma.com, GlaxoSmithKline (GSK) has committed to extracting $2.5 billion in cost savings by optimizing its mature product portfolio, procurement function, and global supply chain — with a major five-year logistics partnership at the center of the effort.
Strategic cost initiative targets mature products and procurement
Under CEO Luke Miels, GSK is intensifying pressure on structural costs beyond R&D and commercial operations. The company explicitly identifies mature products — therapies with established markets and declining growth trajectories — as a primary lever for efficiency gains. Procurement, once viewed as a supporting function, is now positioned as a strategic value driver. As Andrew Witty, former GSK CEO and current board member, stated in Procurement Leaders:
“We continue to apply sustained pressure to GSK’s cost base to realize further savings.”
This directive aligns with industry-wide recalibration: Novartis’s head of productivity strategy, Sammy Rashed, has urged procurement professionals to “break out of the box they’ve built around themselves via the systematic delivery of cost savings.” Similarly, Teva Pharmaceutical Industries’ former CEO Jeremy Levin projected that supply chain and purchasing changes would deliver $400 million to $700 million of his $2 billion cost-cutting plan before his departure in late 2013.
Kuehne + Nagel partnership anchors supply chain transformation
To execute this ambition, GSK has inked a 5-year contract with global logistics provider Kuehne + Nagel. Described by the logistics firm as “transformational for both in its scale and ambition,” the agreement replaces fragmented regional arrangements with an integrated, globally coordinated model. Kuehne + Nagel CEO Detlef Trefzger emphasized the operational scope:
“Our integrated logistics approach, comprising air, sea, overland services and Logistics Control Centers in four regional hubs will enable GSK’s global supply chains to move to the next level of performance.”
The four regional Logistics Control Centers represent a concrete infrastructure commitment — not merely a software or process upgrade. This centralized command-and-control architecture is designed to improve real-time visibility, reduce transit variability, and compress inventory holding periods across GSK’s manufacturing network, which spans multiple continents. The shift reflects a broader pharmaceutical industry trend: supply chain costs, long treated as an afterthought, are now receiving “full attention” as drugmakers seek efficiencies in moving raw materials to plants and finished products to customers worldwide.
Product-centric strategy supports £40B revenue target
While driving cost discipline, GSK is simultaneously advancing its growth agenda through a deliberate “product-centric” operating model. CEO Luke Miels affirmed this focus in his first investor update, declaring:
“We need to be more product-centric as a company.”
This philosophy directs resources toward high-potential assets — notably the two pivotal launches planned for this year: Exdensur, a long-acting respiratory biologic, and Blenrep, an antibody-drug conjugate for myeloma. These launches occur against a backdrop of tempered near-term expectations: GSK forecasts sales growth of just 3% to 5% for the current year. Yet Miels reaffirmed the company’s long-term financial target — set when he served as chief commercial officer — of generating more than £40 billion in revenue by 2031. The dual-track approach — aggressive cost optimization alongside targeted commercial investment — underscores how tightly integrated supply chain and procurement levers are with GSK’s core product strategy.
Source: Fierce Pharma
Compiled from international media by the SCI.AI editorial team.
